

## Article

# Gamma-Delta T-Cell Phenotype and Function in DAA-Treated HIV-HCV Co-Infected and HCV-Mono-Infected Subjects

Valeria Bono <sup>1</sup>, Camilla Tincati <sup>1,\*</sup>, Lorena Van Den Bogaart <sup>2</sup>, Elvira Stefania Cannizzo <sup>1</sup>, Roberta Rovito <sup>1</sup>, Matteo Augello <sup>1</sup> , Anna De Bona <sup>1</sup>, Antonella D'Arminio Monforte <sup>1</sup> , Laura Milazzo <sup>2</sup> and Giulia Marchetti <sup>1</sup>

<sup>1</sup> Clinic of Infectious Diseases and Tropical Medicine, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Via A. di Rudini, 8, 20142 Milan, Italy; valeria.bono@unimi.it (V.B.); stefania.cannizzo@gmail.com (E.S.C.); roberta.rovito@unimi.it (R.R.); matteo.augello@unimi.it (M.A.); anna.debona@asst-santipaolocarlo.it (A.D.B.); antonella.darminio@unimi.it (A.D.M.); giulia.marchetti@unimi.it (G.M.)

<sup>2</sup> III Division of Infectious Diseases, Luigi Sacco Hospital, ASST Fatebenefratelli Sacco, Department of Clinical and Biomedical Sciences, University of Milan, Via G. B. Grassi 74, 20157 Milan, Italy; lorena.vandenbogaart@unimi.it (L.V.D.B.); laura.milazzo@asst-fbf-sacco.it (L.M.)

\* Correspondence: camilla.tincati@unimi.it; Tel./Fax: +39-02-8184-3064

**Abstract:** HIV-HCV co-infected subjects are at risk of liver fibrosis which may be linked to immune imbalances. Direct-acting antivirals (DAAs) represent the mainstay of HCV treatment in co-infected individuals, yet their effects on immune cell populations playing a role in fibrogenesis is unknown. We assessed  $\gamma\delta$  T-cell phenotype and function, Treg and Th17 frequencies, as well as  $\gamma$ -globulins and B-cell activation in 47 HIV-HCV co-infected and 35 HCV mono-infected individuals prior to and following DAA treatment (SVR12).  $\Gamma\delta$  T-cell activation decreased in both groups yet persisted at higher levels in the HIV-HCV co-infected subjects. No differences were registered in terms of  $\gamma\delta$ T-cell function. Of note, the V $\delta$ 2/Th17 ratio, inversely linked to liver damage, increased significantly in the two groups upon treatment, yet a negative correlation between the V $\delta$ 2/Th17 ratio and liver function enzymes was found in the co-infected subjects alone. B-cell activation and  $\gamma$ -globulin levels decreased in both settings, yet B-cell activation remained higher in the HIV-HCV co-infected individuals. In HIV-HCV co-infected and HCV mono-infected participants, the effect of DAA was limited to  $\gamma\delta$  T- and B-cell activation as well as  $\gamma$ -globulin concentrations and the V $\delta$ 2/Th17 ratio, with no changes in  $\gamma\delta$  T-cell function and Treg frequencies. Importantly,  $\gamma\delta$  T- and B-cell activation remained at higher levels in the co-infected individuals than in those with HCV mono-infection alone. The persistence of such alterations within these cell subsets may be associated with the risk of hepatic and extrahepatic complications.

**Keywords:**  $\gamma\delta$  T-cells; Th17-cells; Treg cells; B-cells; HCV; HIV; DAA; liver damage



**Citation:** Bono, V.; Tincati, C.; Van Den Bogaart, L.; Cannizzo, E.S.; Rovito, R.; Augello, M.; De Bona, A.; D'Arminio Monforte, A.; Milazzo, L.; Marchetti, G. Gamma-Delta T-Cell Phenotype and Function in DAA-Treated HIV-HCV Co-Infected and HCV-Mono-Infected Subjects. *Viruses* **2022**, *14*, 1594. <https://doi.org/10.3390/v14081594>

Academic Editor: Miguel A. Martínez

Received: 14 May 2022

Accepted: 20 July 2022

Published: 22 July 2022

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## 1. Introduction

HIV-HCV co-infected subjects are at risk of accelerated liver fibrosis [1] and disease progression. The underlying causes are multifactorial and include, yet are not limited to, life-style habits, uncontrolled HIV replication, and the use of combination antiretroviral therapy (cART) [1].

Immune skewing in HIV-HCV co-infected individuals may represent a key element of hepatic fibrosis [2]. Indeed, a solid bulk of the literature has demonstrated that enduring immune abnormalities, despite effective antiviral therapy against either HIV or HCV, may be a pathogenic feature of hepatic disease progression in HIV infection [3–10].

Direct-acting antivirals (DAAs) currently represent the mainstay of anti-HCV treatment in HCV and HIV-HCV co-infected populations, given their ease of administration, clinical efficacy, and tolerability. Further, in both clinical settings, DAA treatment is able to lower the expression of activation and senescence markers on T-cells as well as the levels of

inflammatory markers in the peripheral blood [11,12]. However, in HCV mono-infection, DAAs fail to restore the frequency and function of Th17, Treg [13], and  $\gamma\delta$ T-cells [14,15] which are known to play a pivotal role in fibrogenesis [16–20] and, in the case of Tregs, may also contribute to the pathogenesis of extrahepatic manifestations in chronic HCV disease [21]. Scant data are available on the effects of DAA treatment on Treg and  $\gamma\delta$ T-cells subsets in HIV-HCV co-infection. Indeed, with the exception of one study reporting impaired IFN- $\gamma$  production in  $\gamma\delta$ T-cells in treated HIV-HCV co-infection [22], the impact of DAA therapy on these cell populations in the co-infected individuals is largely unknown.

To bridge this gap, we investigated the changes in  $\gamma\delta$ T-cells activation and function as well as Th17 and Treg cell frequencies,  $\gamma$ -globulins, and B-cell activation in a cohort of DAA-treated HIV-HCV co-infected and HCV mono-infected individuals.

## 2. Methods

### 2.1. Study Population

We enrolled HIV-HCV co-infected and HCV mono-infected subjects that were undergoing treatment with DAAs. Both groups were studied prior to (baseline, BL) and at 12 weeks after the end of treatment (EoT), corresponding to a Sustained Virological Response (SVR12). The co-infected HIV-HCV subjects were all virally suppressed for HIV on cART.

The local Institutional Review Board approved the study, and written signed informed consent was obtained from all the patients.

### 2.2. Immune Studies

Peripheral blood mononuclear cells (PBMCs) were isolated from EDTA tube-collected venous blood by means of Ficoll-Histopaque (Biocoll, BIOSPA, Milano, Italia), cryopreserved in fetal bovine serum (EuroClone) with 10% Dimethyl Sulfoxide (EuroClone), and then stored in liquid nitrogen. The lymphocyte percentages, phenotypes, and functions were evaluated by flow cytometry on thawed PBMCs. The following antibodies were used: CD3 (BV510), CD4 (APC), CD19 (APC), TCR- $\gamma\delta$  (FITC), V $\delta$ 2 (BB700), CCR6 (PECy-7), CD161 (BB700), CD25 (BV421), CD127 (BB515), CD38 (PE), CD69 (BV421), CD86 (PECy-7), IFN- $\gamma$  (PE), TNF- $\alpha$  (PECy-7), IL-17A (BV421), CD107a (PECy-7), and Granzyme B (PE) (BD Biosciences, Franklin Lakes, NJ, USA). Dead cells were labeled using Viability™ Fixable Dye (Miltenyi Biotec, Bergisch Gladbach, Germany). Combinations that were used were: CD4 + CCR6 + CD161 + (Th17); CD3 + pan-TCR $\gamma\delta$  + ( $\gamma\delta$  T-cells), CD4 + CD25 + CD127 – (Treg cells); CD3 + TCR $\gamma\delta$  + CD69+/CD38 +  $\gamma\delta$  T-cell activation), CD3 + TCR $\gamma\delta$  + GrB+/CD107a+/IFN $\gamma$ +/TNF $\alpha$ +/IL-17A + ( $\gamma\delta$  T-cell functions); and CD3 – CD19 + CD69+/CD86 + (B-cells activation).

For surface marker staining,  $1 \times 10^6$  PBMCs were stained with the appropriate antibodies for 20 min at 4 °C in the dark and acquired using FACSVerse™ cytometer (BD Biosciences).

For intracellular cytokine staining,  $1.5 \times 10^6$  PBMCs were stimulated with phorbol myristate acetate (PMA) and ionomycin (Sigma Aldrich Merck, Burlington, MA, USA) (25 ng/mL and 1  $\mu$ g/mL, respectively) for 5 h, whereas negative controls were left untreated. Brefeldin A (1 mg/mL, Sigma Aldrich) was added after 1 h stimulation. The cells were harvested and stained with surface antibodies; after paraformaldehyde (PFA) fixation (1%, Sigma-Aldrich), the cells were permeabilized with Saponin 0.2% (Sigma-Aldrich) and stained with intracellular cytokines for 30 min at room temperature (RT) and acquired using the FACSVerse™ cytometer (BD Biosciences).

An example of the gating strategy that was used is presented in Supplementary Figures S1–S3.

### 2.3. $\gamma$ -Globulins Quantification

The quantification of  $\gamma$ -globulins was performed by means of serum protein electrophoresis by the central laboratory of “L. Sacco” Hospital, Milan, Italy.

## 2.4. Statistics

The data were analyzed and graphed with GraphPad Prism Software. Categorical variables are presented as the total number and percentage values. Continuous variables are presented as the median and interquartile range (IQR). A Wilcoxon matched-pairs test was applied for longitudinal analysis between T0 and SVR12 in the HIV-HCV co-infected group and in the HCV infection group. A Mann–Whitney test was applied for cross-sectional analysis of all study groups.

## 3. Results

### 3.1. Study Population

A total of 47 HIV-HCV co-infected and 35 HCV mono-infected individuals were included in the study. The demographic and clinical characteristics of the study population are summarized in Table 1. The HIV-related parameters in the HIV-HCV co-infected subjects are presented in Table 2.

The two study groups were comparable in terms of demographic and hepatic disease characteristics. All the subjects achieved SVR12 after DAA treatment.

**Table 1.** Demographic and clinical characteristic of the study subjects.

	HIV-HCV (N = 47)	HCV (N = 35)	<i>p</i> -Value
Male, <i>n</i> (%)	37 (79)	22 (63)	0.13
Age (years), median (IQR)	52 (48–57)	54 (47–62)	0.66
Time since HCV diagnosis, years (IQR)	12 (4–23)	14 (2–20)	0.22
HCV genotype, <i>n</i> (%)			
1	23 (49)	17 (48)	0.8
2	2 (4)	5 (14)	
3	15 (32)	4 (11)	
4	7 (15)	8 (23)	
5	0	1 (3)	
Liver fibrosis			
Stiffness < 9.5 KPa (F0–F2)	35 (74)	28 (80)	0.7
Stiffness ≥ 9.5 KPa (F3–F4)	11 (23)	7 (20)	
DAA regimen, <i>n</i> (%)			
ombitasvir/paritaprevir/rtv	1 (2.1)	2 (5.7)	0.02
ombitasvir/paritaprevir/rtv + dasabuvir	2 (4.2)	3 (8.6)	
glecaprevir/pibrentasvir	9 (19.1)	17 (48.6)	
ledipasvir/sofosbuvir + rbv	4 (3.5)	0 (0)	
sofosbuvir/daclatasvir	6 (12.8)	2 (5.7)	
sofosbuvir/velpatasvir	18 (38.3)	5 (14.3)	
elbasvir/grazoprevir	5 (10.7)	5 (14.3)	
ombitasvir + rbv	2 (4.2)	0 (0)	
sofosbuvir/daclatasvir + rbv	0 (0)	1 (2.9)	
DAA duration, <i>n</i> (%)			
8 weeks	9 (19)	12 (34)	0.2
12 weeks	34 (72)	21 (30)	
24 weeks	4 (8)	2 (6)	
Liver transaminases at SVR12			
AST, IU/L (median, IQR)	25 (20–30)	21 (17–28)	0.2
ALT, IU/L (median, IQR)	24 (15–32)	20 (13–26)	0.2

Legend: Liver fibrosis assessed by elastography; DAA: Direct Acting Antivirals; rtv: ritonavir; rbv: ribavirin.

**Table 2.** HIV-related parameters in the HIV-HCV co-infected subjects.

	HIV/HCV
	(N = 47)
Time since HIV diagnosis, years (IQR)	17 (11–25)
CD4% at T0, median (IQR)	28 (22–34)
CD4, cell/mm <sup>3</sup> at T0, (IQR)	612 (327–831)
CD4/CD8 ratio, median (IQR)	0.66 (0.49–0.95)
Patients with HIV/RNA < 40 cp/mL, n (%)	47 (100)

### 3.2. $\gamma\delta$ T-Cell Activation and Function during DAA Treatment

No major changes were observed in the  $\gamma\delta$  T-cell percentages in the two groups, however, at SVR12, the HIV-HCV co-infected subjects showed significantly higher  $\gamma\delta$  T-cell frequencies than the HCV mono-infected individuals (2.99% [IQR: 2.81–3.22] vs. 2.34% [IQR: 1.89–2.89];  $p$ -value < 0.0001) (Figure 1A).

The magnitude of activated  $\gamma\delta$  T-cells and the functionality of total  $\gamma\delta$  T-cells in the HIV-HCV co-infected and HCV mono-infected subjects were assessed prior and following DAA treatment. A significant contraction of activated  $\gamma\delta$  T-cells, i.e., CD69 +  $\gamma\delta$  T-cells and CD38 +  $\gamma\delta$  T-cells, was observed at SVR12 in individuals with HIV-HCV co-infection (CD69 +  $\gamma\delta$  +: 11% [IQR: 8.7–14]; 8.6% [IQR: 5.2–12];  $p$  = 0.02; CD38 +  $\gamma\delta$  +: 55% [IQR: 33.5–68]; 39% [IQR: 32.1–53];  $p$  = 0.01) and HCV mono-infection (CD69 +  $\gamma\delta$  +: 10.3% [IQR: 6.7–11.6]; 6.5% [IQR: 4–8.3];  $p$  = 0.01; CD38 +  $\gamma\delta$  +: 38.9% [IQR: 30.5–55.8]; 27.4% [IQR: 22–38–8];  $p$  = 0.03) (Figure 1B). Of note, at SVR12, the HIV-HCV co-infected subjects displayed significantly higher CD69 +  $\gamma\delta$  + ( $p$  = 0.02), as well as CD38 +  $\gamma\delta$  + T-cells ( $p$  = 0.003) as compared to individuals with HCV mono-infection (Figure 1A,B).


We also evaluated cytokine production i.e., Granzyme B, CD107, IFN- $\gamma$ , TNF- $\alpha$ , and IL-17A from  $\gamma\delta$  T-cells in the course of DAA treatment. With the exception of lower baseline Granzyme B +  $\gamma\delta$ + T-cells in the co-infected individuals (29.5% [IQR: 18.6–53.2] vs. 81.8% [IQR: 30.1–93.7];  $p$  = 0.01; Figure 1C), possibly suggesting functional exhaustion in this setting, no other significant difference was observed between the groups or in cytokine production change within the same group during therapy.

Similarly, V $\delta$ 2 T-cells were homogenous between the groups with a non-significant rise in the course of DAA treatment in both groups: HIV-HCV co-infected (T0: 16.9% [IQR: 4.9–24.5]; SVR 12: 13.4% [IQR: 10.5–23.06];  $p$  = 0.7) and HCV mono-infected (T0: 14.4% [IQR: 7.2–3.9]; SVR 12: 18.1% [IQR: 11.5–26.8]  $p$  = 0.2) individuals (Figure 1D).


### 3.3. Treg and Th17-Cells during DAA Treatment

We next investigated the trend of Treg and Th17-cell frequencies during the DAA treatment in the two study groups. No differences were observed in Treg (Figure 2A) and Th17-cells, aside from a significant decrease of the latter in the HIV-HCV co-infected subjects (T0: 1.92% [IQR: 1.76–2.47]; SVR 12: 1.62% [IQR: 1.1–2.39];  $p$  = 0.04) following successful DAA treatment (Figure 2B).

The V $\delta$ 2/Th17 ratio increased significantly in subjects with HIV-HCV co-infection (T0: 6.3% [IQR: 2.56–12.7]; SVR 12: 11.03% [IQR: 6.04–14.24];  $p$  = 0.03) and HCV mono-infection (T0: 8.63% [IQR: 5.08–10.5]; SVR12: 11.56% [IQR: 7.01–15.48];  $p$  = 0.02) (Figure 2C). No statistically significant correlation was found between the V $\delta$ 2/Th17 ratio and transaminase levels as well as liver stiffness measurements at baseline in both groups (co-infection: AST:  $r$  = 0.2,  $p$  = 0.1; ALT:  $r$  = 0.2;  $p$  = 0.09; stiffness:  $r$  = 0.06,  $p$  = 0.7; mono-infection: AST:  $r$  = 0.1,  $p$  = 0.4; ALT:  $r$  = 0.1;  $p$  = 0.5; stiffness:  $r$  = 0.19,  $p$  = 0.3); however, upon successful treatment, a negative correlation was found between the V $\delta$ 2/Th17 ratio and liver function enzymes in co-infected subjects alone (AST:  $r$  = −0.3,  $p$  = 0.05; ALT:  $r$  = −0.4,  $p$  = 0.01) (Figure 2D), whereas no correlation was found in the mono-infected individuals (AST:  $r$  = −0.03,  $p$  = 0.8; ALT:  $r$  = 0.2,  $p$  = 0.2) (Figure 2E).




**Figure 1.**  $\gamma\delta$  T-cell phenotype, activation, function, and V $\delta$ 2 T-cells in the HIV-HCV co-infected and HCV mono-infected individuals that were undergoing DAA treatment. **(A)** Frequencies of  $\gamma\delta$  T-cells in the HIV-HCV co-infected and HCV mono-infected individuals prior and following DAA treatment. Wilcoxon matched-pairs test ( $n = 40$  and  $n = 35$ ) and Mann–Whitney test. For this experiment, the HIV mono-infected individuals ( $n = 15$ ; bold line) and healthy controls ( $n = 10$ ; dotted line) are also shown. The HCV mono-infected individuals showed significantly lower  $\gamma\delta$  T-cell frequencies after DAA treatment than the healthy controls (2.34% [IQR: 1.89–2.89] vs. 3.44% [IQR: 2.4–4.61]  $p$ -value = 0.006). **(B)** Frequencies of activated CD69+ and CD38+  $\gamma\delta$  T-cells in the HIV-HCV co-infected and HCV mono-infected individuals prior and following DAA treatment. Wilcoxon matched-pairs test ( $n = 47$  and  $n = 35$ ) and Mann–Whitney test. **(C)** Frequencies of Granzyme B, CD107a, IFN- $\gamma$ , TNF- $\alpha$ , and IL17A producing  $\gamma\delta$  T-cells in the HIV-HCV co-infected and HCV mono-infected individuals prior and following DAA treatment. Wilcoxon matched-pairs test ( $n = 25$  and  $n = 15$ ) and Mann–Whitney test. **(D)** Frequencies of V $\delta$ 2 T-cells in the HIV-HCV co-infected and HCV mono-infected individuals prior and following DAA treatment. Wilcoxon matched-pairs test ( $n = 31$  and  $n = 26$ ) and Mann–Whitney test.



**Figure 2.** Treg, Th17, and Vδ2/Th17 ratio and correlation between Vδ2/Th17 ratio and liver function enzymes in the HIV-HCV co-infected and HCV mono-infected individuals that were undergoing DAA treatment. (A) Frequencies of Treg in the HIV-HCV co-infected and HCV mono-infected individuals prior and following DAA treatment. Wilcoxon matched-pairs test ( $n = 38$  and  $n = 35$ ) and Mann–Whitney test. For this experiment, HIV mono-infected individuals ( $n = 15$ ; bold line) and healthy controls ( $n = 10$ ; dotted line) are also shown. The HCV mono-infected individuals showed significantly higher Treg cell frequencies than the healthy controls both before and after DAA treatment (T0: 2.3% [IQR: 1.7–5.7] vs. 0.82% [IQR: 0.62–1.95];  $p$ -value = 0.0001; SVR 12: 3% [IQR: 1.87–5.22] vs. 0.82% [IQR: 0.62–1.95];  $p = 0.0002$ ) (B) The frequencies of Th17 in the HIV-HCV co-infected and HCV mono-infected individuals prior and following DAA treatment. Wilcoxon matched-pairs test ( $n = 43$  and  $n = 35$ ) and Mann–Whitney test. For this experiment, the HIV mono-infected individuals ( $n = 15$ ; bold line) and healthy controls ( $n = 10$ ; dotted line) are also shown. HCV mono-infected individuals showed significantly lower Th17-cell frequencies than the healthy controls both before and after DAA treatment (T0: 1.75% [IQR: 1–3] vs. 3.92% [IQR: 3.38–5.62]  $p$ -value = 0.002; SVR 12: 1.71% [IQR: 1.17–2.1] vs. 3.92% [IQR: 3.38–5.62];  $p < 0.0001$ ) (C) The Vδ2/Th17 ratio in HIV-HCV co-infected and HCV mono-infected individuals prior and following DAA treatment. Wilcoxon matched-pairs test ( $n = 31$  and  $n = 26$ ) and Mann–Whitney test. (D) Spearman’s correlation between Vδ2/Th17 ratio and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in 31 HIV-HCV co-infected individuals after DAA treatment. (E) Spearman’s correlation between Vδ2/Th17 ratio and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in 25 HCV mono-infected individuals after DAA treatment.

### 3.4. B-Cell Activation and $\gamma$ -Globulins during DAA Treatment

Given that persistent Treg imbalances together with enduring B-cell activation contribute to the pathogenesis of extrahepatic manifestations of chronic HCV infection, such as cryoglobulinemic vasculitis and B-cell lymphoma [21], we also studied the magnitude of activated B-cells in the study groups prior to and following DAA treatment. A significant contraction of activated CD69 + B-cells was observed in both the HIV-HCV co-infected (4.8% [IQR: 2.7–7.3]; 3.1% [IQR: 1.5–6];  $p = 0.02$ ) and HCV mono-infected (2.3% [IQR: 2.1–5.2]; 2% [IQR 1.3–3.8];  $p = 0.01$ ) individuals. (Figure 3A). Despite these changes, significantly higher CD69-expressing B-cells were found in the HIV-HCV co-infected compared to HCV mono-infected subjects at baseline (4.9% [IQR: 2.7–7.3] vs. 2.3% [IQR: 2.1–5.2];  $p = 0.005$ ) and after DAA treatment (3.1% [IQR: 1.5–6] vs. 2% [IQR: 1.3–3.8];  $p = 0.002$ ).



**Figure 3.** B-cell activation and  $\gamma$ -globulins in the HIV-HCV co-infected and HCV mono-infected individuals that were undergoing DAA treatment. (A) Frequencies of activated CD69+ and CD86+ B-cells in the HIV-HCV co-infected and HCV mono-infected individuals prior and following DAA treatment. Wilcoxon matched-pairs test ( $n = 47$  and  $n = 35$ ) and Mann–Whitney test. (B)  $\gamma$ -globulins in the HIV-HCV co-infected and HCV mono-infected individuals prior and following DAA treatment. Wilcoxon matched-pairs test ( $n = 26$  and  $n = 20$ ) and Mann–Whitney test.

A similar, albeit not statistically significant, decrease in activated CD86 + B-cells was also observed in the course of the study (Figure 3A).

Finally, a significant contraction of  $\gamma$ -globulin levels was observed in both the HIV-HCV co-infected (18.3% [IQR: 16.18–22.73]; 17.10% [IQR: 15–20.65];  $p = 0.003$ ) and HCV mono-infected individuals (19.2% [IQR: 16.53–21.8]; 17.1% [15.95–18.83];  $p = 0.002$ ) after DAA treatment (Figure 3B).

#### 4. Discussion

Co-infection with HCV has been described as a co-factor contributing to persistent immune dysfunction in HIV-infected cART-treated, aviremic people living with HIV (PLWH) [23], which, in turn, may also influence hepatic disease progression [24].

DAAs exert a partial effect on peripheral immune imbalances in co-infected subjects; indeed, they are able to induce the phenotypic and functional recovery of HCV-specific CD8 T-lymphocytes [25] and NK-cells [26], yet not of mucosal-associated invariant T-cells (MAIT) [27]. Yet, to our knowledge, few papers have explored the effects of DAAs on key immune cell populations in fibrogenesis, namely  $\gamma\delta$  T, Treg, Th17, and B-cells [16–19], in HIV-HCV co-infected subjects [22].

In the present paper, we evaluated the kinetics of these cell subsets in a cohort of DAA-treated individuals with HIV-HCV co-infection and HCV mono-infection.  $\Gamma\delta$  T-cell activation, measured through the expression of surface markers CD38 and CD69, decreased in both groups following successful anti-HCV treatment, yet persisted at significantly higher levels in the co-infected individuals. In contrast,  $\gamma\delta$  T-cell function that was assessed by Granzyme B, CD107a, IFN- $\gamma$ , TNF- $\alpha$ , and IL-17A production remained unchanged in both groups. Our results suggest that HCV eradication that was obtained by DAA treatment affects only  $\gamma\delta$  T-cell phenotype and not function. Indeed, despite lacking a control group of HIV mono-infected and/or healthy uninfected donors, our findings are in keeping with prior evidence by Cimini et al. who demonstrated decreased V $\delta$ 2 cell activation in the DAA-treated, HIV-HCV co-infected individuals, yet maintenance at higher levels compared to healthy donors, with little/no effect on IFN- $\gamma$  production [22]. Our findings currently lack data on activated V $\delta$ 1 cells, which have been shown to play a role in hepatic disease progression in co-infected individuals regardless of cART [20]. The effect of DAA on the reported increase of V $\delta$ 1 cells in HIV-HCV co-infection is unknown and needs to be explored in this setting.

We also report a non-significant rise of V $\delta$ 2 cells in co-infected individuals, which, coupled with a decrease in Th17 frequencies, resulted in a significant increase of the V $\delta$ 2/Th17 ratio. In accordance with data demonstrating that the V $\delta$ 2/Th17 ratio is inversely linked to hepatic damage [28], we found a negative correlation between the V $\delta$ 2/Th17 ratio and liver function enzymes, albeit within the normal range, in the setting of co-infection alone. An increase in the V $\delta$ 2/Th17 ratio was also observed in mono-infected subjects but it appeared to be less consistent than that of co-infected individuals, given the lack of significant rise in V $\delta$ 2 and/or decrease in Th17-cells as well as the absence of a statistical correlation with liver transaminases. These results point to a possible differential effect of HCV clearance in HIV-HCV co-infected and HCV mono-infected subjects linked to  $\gamma\delta$  T and Th17 subsets and complement prior evidence by Farcomeni et al. showing greater differences in T-cell phenotype changes in co-infected individuals [29]. Further, in keeping with the concept that was suggested by Wu et al. [28] of the interaction between the two cell subsets in driving liver inflammation and together with the notion of low-level inflammation in treated HIV subjects [23], our findings may suggest subclinical evidence of hepatic damage in the setting of HIV-HCV co-infection.

Finally, we describe decreases in the  $\gamma$ -globulin concentrations following DAA-mediated SVR which may relate to the reduction in peripheral, activated B-cells. However, our data also show enduring B-cell activation in HIV-HCV co-infection possibly meaning a maintained a risk of developing extra-hepatic manifestations that are associated with prior HCV infection [21].

Our analyses were limited to the SVR12 post-DAA timing, thus a long-term effect of HCV eradication on the T- and B-cell function recovery cannot be ruled out. Indeed, elevated immune activation may persist long after the end of treatment and contribute to post-SVR consequences.

In conclusion, we show a benefit of HCV eradication that is mediated by DAA treatment in HIV-HCV and HCV mono-infected subjects, with decreased activation of  $\gamma\delta$  T- and B-cells as well as increases in the V $\delta$ 2/Th17 ratio and reduced  $\gamma$ -globulin concentrations.

These findings shed light onto the possible immunopathogenic mechanisms underlying the improvement of liver function following HCV clearance. However,  $\gamma\delta$  T- and B-cell activation remained at higher levels in HIV-HCV co-infection than that which was measured in HCV mono-infection alone. Given the enduring clinical risk of cART-treated HIV-infected subjects [23] and the high rates of subsequent HCV re-infection in this population [30], future studies are needed to elucidate the impact of DAA therapy on long-term immune imbalances in HIV-HCV co-infected individuals.

**Supplementary Materials:** The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/v14081594/s1>, Figure S1: Gating strategy for Th17 and Treg cells; Figure S2: Gating strategy for  $\gamma\delta$  cells; Figure S3: Gating strategy for B-cells

**Author Contributions:** V.B., L.V.D.B., E.S.C. and R.R. performed experiments and analyzed the data. C.T., L.M. and G.M. conceived the study. V.B., C.T., L.M. and G.M. wrote the manuscript. L.V.D.B., M.A., A.D.B. and L.M. were involved in clinical care of patients and revised the manuscript. A.D.M., L.M. and G.M. supervised the study. All authors have read and agreed to the published version of the manuscript.

**Funding:** The present research was funded by: (i) Piano di Sostegno alla Ricerca 2015/2017, Linea 2, Università degli Studi di Milano (recipient: CT); (ii) Programmi di Rete 2013, NET-2013-02355333-3, Ministero della Salute (recipient: GM). The authors acknowledge the support of the APC central fund of the University of Milan.

**Institutional Review Board Statement:** The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Ethics Committee (Comitato Etico ASST Santi Paolo e Carlo; 2020/ST/049, 2020/ST/049\_BIS, 11/03/2020).

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study.

**Data Availability Statement:** Data that support the findings of this study are available upon reasonable request to the corresponding author.

**Acknowledgments:** We are grateful to all patients who participated in the study and to the staff of the hospitals who cared for the patients.

**Conflicts of Interest:** All authors have no conflict of interest to declare.

## References

1. Chrysanthis, T.; Loli, G.; Metallidis, S.; Germanidis, G. Mechanisms of Accelerated Liver Fibrosis in HIV-HCV Coinfection. *Aids Rev.* **2017**, *19*, 148–155. [[CrossRef](#)] [[PubMed](#)]
2. Sacchi, P.; Cima, S.; Zuccaro, V.; Columpsi, P.; Sarda, C.; Mariani, M.; Puoti, M.; Bruno, R. Understanding the Mechanisms of Fibrogenesis in HIV/HCV-Coinfected Patients: Implications for Clinical Practice. *Aids Rev.* **2015**, *17*, 159–170. [[PubMed](#)]
3. Marchetti, G.; Nasta, P.; Bai, F.; Gatti, F.; Bellistri, G.M.; Tincati, C.; Borghi, F.; Carosi, G.; Puoti, M.; Monforte, A.d. Circulating sCD14 is associated with virological response to pegylated-interferon-alpha/ribavirin treatment in HIV/HCV co-infected patients. *PLoS ONE* **2012**, *7*, e32028.
4. Nyström, J.; Stenkvist, J.; Häggblom, A.; Weiland, O.; Nowak, P. Low levels of microbial translocation marker LBP are associated with sustained viral response after anti-HCV treatment in HIV-1/HCV co-infected patients. *PLoS ONE* **2015**, *10*, e0118643.
5. Judge, C.J.; Sandberg, J.; Funderburg, N.; Sherman, K.E.; Butt, A.A.; Kang, M.; Landay, A.L.; Lederman, M.M.; Anthony, D.D. Brief Report: CD14<sup>bright</sup>CD16<sup>−</sup> monocytes and sCD14 level negatively associate with CD4-memory T-cell frequency and predict HCV-decline on therapy. *JAIDS J. Acquir. Immune Defic. Syndr.* **2016**, *73*, 258–262. [[CrossRef](#)]
6. Kared, H.; Saeed, S.; Klein, M.; Shoukry, N.H. CD127 Expression, Exhaustion Status and Antigen Specific Proliferation Predict Sustained Virologic Response to IFN in HCV/HIV Co-Infected Individuals. *PLoS ONE* **2014**, *9*, e0101441. [[CrossRef](#)]
7. Grubczak, K.; Grzeszczuk, A.; Groth, M.; Hryniewicz, A.; Kretowska-Grunwald, A.; Flisiak, R.; Moniuszko, M. Effects of Pegylated Interferon Alpha and Ribavirin (pegIFN- $\alpha$ /RBV) Therapeutic Approach on Regulatory T Cells in HCV-Monoinfected and HCV/HIV-Coinfected Patients. *Viruses* **2021**, *13*, 1448. [[CrossRef](#)]
8. Kushner, L.E.; Wendelboe, A.M.; Lazzeroni, L.C.; Chary, A.; Winters, M.A.; Osinusi, A.; Kottlil, S.; Polis, M.A.; Holodny, M. Immune Biomarker Differences and Changes Comparing HCV Mono-Infected, HIV/HCV Co-Infected, and HCV Spontaneously Cleared Patients. *PLoS ONE* **2013**, *8*, e60387. [[CrossRef](#)]
9. Arizcorreta, A.; Márquez, M.; Fernández-Gutiérrez, C.; Guzmán, E.P.; Brun, F.; Rodríguez-Iglesias, M.; Girón-González, J.A. T cell receptor excision circles (TRECs), CD4<sup>+</sup>, CD8<sup>+</sup> and their CD45RO<sup>+</sup> and CD45RA<sup>+</sup> subpopulations in hepatitis C virus (HCV)-HIV-co-infected patients during treatment with interferon alpha plus ribavirin: Analysis in a population on effective antiretroviral therapy. *Clin. Exp. Immunol.* **2006**, *146*, 270–277. [[CrossRef](#)]

10. Brochado, Ó.; the GESIDA Study Group; Martínez, I.; Berenguer, J.; Medrano, L.; González-García, J.; Jiménez-Sousa, M.; Carrero, A.; Hontañón, V.; Navarro, J.; et al. HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients. *J. Biomed. Sci.* **2021**, *28*, 1–14. [[CrossRef](#)]
11. Wedemeyer, H.; Khera, T.; Strunz, B.; Björkström, N.K. Reversal of Immunity After Clearance of Chronic HCV Infection-All Reset? *Front. Immunol.* **2020**, *11*, 571166. [[CrossRef](#)] [[PubMed](#)]
12. Hengst, J.; Falk, C.S.; Schlaphoff, V.; Deterding, K.; Manns, M.P.; Cornberg, M.; Wedemeyer, H. Direct-Acting Antiviral-Induced Hepatitis C Virus Clearance Does Not Completely Restore the Altered Cytokine and Chemokine Milieu in Patients with Chronic Hepatitis C. *J. Infect. Dis.* **2016**, *214*, 1965–1974. [[CrossRef](#)] [[PubMed](#)]
13. Langhans, B.; Nischalke, H.D.; Krämer, B.; Hausen, A.; Dold, L.; van Heteren, P.; Huneburg, R.; Natterman, J.; Strassburg, C.P.; Spengler, U. Increased peripheral CD4 + regulatory T cells persist after successful direct-acting antiviral treatment of chronic hepatitis C. *J. Hepatol.* **2017**, *66*, 888–896. [[CrossRef](#)] [[PubMed](#)]
14. Ghosh, A.; Mondal, R.K.; Romani, S.; Bagchi, S.; Cairo, C.; Pauza, C.D.; Kottlil, S.; Poonia, B. Persistent gamma delta T-cell dysfunction in chronic HCV infection despite direct-acting antiviral therapy induced cure. *J. Viral Hepat.* **2019**, *26*, 1105–1116. [[CrossRef](#)]
15. Ravens, S.; Hengst, J.; Schlapphoff, V.; Deterding, K.; Dhingra, A.; Schultze-Florey, C.; Koenecke, C.; Cornberg, M.; Wedemeyer, H.; Prinz, I. Human  $\gamma\delta$  T Cell Receptor Repertoires in Peripheral Blood Remain Stable Despite Clearance of Persistent Hepatitis C Virus Infection by Direct-Acting Antiviral Drug Therapy. *Front. Immunol.* **2018**, *9*, 510. [[CrossRef](#)]
16. Sturm, N.; Thélou, M.-A.; Camous, X.; Dimitrov, G.; Ramzan, M.; Dufeu-Duchesne, T.; Bonorino, P.; Guillermet, C.; Brambilla, E.; Arvers, P.; et al. Characterization and role of intra-hepatic regulatory T cells in chronic hepatitis C pathogenesis. *J. Hepatol.* **2010**, *53*, 25–35. [[CrossRef](#)]
17. Rios, D.A.; Valva, P.; Casciato, P.C.; Frias, S.; Soledad Caldirola, M.; Gaillard, M.I.; Bezrodnik, L.; Bandi, J.; Galdame, O.; Ameigeiras, B.; et al. Chronic hepatitis C liver microenvironment: Role of the Th17/Treg interplay related to fibrogenesis. *Sci. Rep.* **2017**, *7*, 13283. [[CrossRef](#)]
18. Ikeno, Y.; Ohara, D.; Takeuchi, Y.; Watanabe, H.; Kondoh, G.; Taura, K.; Uemoto, S.; Hirota, K. Foxp3+ Regulatory T Cells Inhibit CCl4-Induced Liver Inflammation and Fibrosis by Regulating Tissue Cellular Immunity. *Front. Immunol.* **2020**, *11*, 584048. [[CrossRef](#)]
19. Liu, M.; Hu, Y.; Yuan, Y.; Tian, Z.; Zhang, C.  $\gamma\delta$ T Cells Suppress Liver Fibrosis via Strong Cytotoxicity and Enhanced NK Cell-Mediated Cytotoxicity Against Hepatic Stellate Cells. *Front. Immunol.* **2019**, *10*, 477. [[CrossRef](#)]
20. Agrati, C.; D'Offizi, G.; Narciso, P.; Selva, C.; Pucillo, L.P.; Ippolito, G.; Poccia, F. Gammadelta T cell activation by chronic HIV infection may contribute to intrahepatic vdelta1 compartmentalization and hepatitis C virus disease progression independent of highly active antiretroviral therapy. *AIDS Res. Hum. Retrovir.* **2001**, *17*, 1357–1363. [[CrossRef](#)]
21. Cacoub, P.; Saadoun, D. Extrahepatic Manifestations of Chronic HCV Infection. *N. Engl. J. Med.* **2021**, *384*, 1038–1052. [[CrossRef](#)] [[PubMed](#)]
22. Cimini, E.; Sacchi, A.; Grassi, G.; Casetti, R.; Notari, S.; Bordoni, V.; Forini, O.; Grilli, E.; Vergori, A.; Capobianchi, M.R.; et al. Persistent gamma delta T-cell dysfunction in HCV/HIV co-infection despite direct-acting antiviral therapy-induced cure. *J. Viral Hepat.* **2020**, *27*, 754–756. [[CrossRef](#)]
23. Deeks, S.G.; Lewin, S.R.; Havlir, D.V. The end of AIDS: HIV infection as a chronic disease. *Lancet* **2013**, *382*, 1525–1533. [[CrossRef](#)]
24. Marchetti, G.; for the ICONA Foundation Study Group; Cozzi-Lepri, A.; Tincati, C.; Calcagno, A.; Ceccherini-Silberstein, F.; De Luca, A.; Antinori, A.; Castagna, A.; Puoti, M.; et al. Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: Results from the Icona Foundation study. *BMC Infect. Dis.* **2014**, *14*, 79. [[CrossRef](#)] [[PubMed](#)]
25. Wieland, D.; Kemming, J.; Schuch, A.; Emmerich, F.; Knolle, P.; Neumann-Haefelin, C.; Held, W.; Zehn, D.; Hofmann, M.; Thimme, R. TCF1+ hepatitis C virus-specific CD8+ T cells are maintained after cessation of chronic antigen stimulation. *Nat. Commun.* **2017**, *8*, 15050. [[CrossRef](#)] [[PubMed](#)]
26. Serti, E.; Chepa-Lotrea, X.; Kim, Y.J.; Keane, M.; Fryzek, N.; Liang, T.J.; Ghany, M.; Rehmann, B. Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function. *Gastroenterology* **2015**, *149*, 190–200.e2. [[CrossRef](#)]
27. Cannizzo, E.S.; Cerrone, M.; Merlini, E.; Van Wilgenburg, B.; Swadling, L.; Ancona, G.; De Bona, A.; Monforte, A.D.; Klenerman, P.; Marchetti, G. Successful direct-acting antiviral therapy in HIV/HCV co-infected patients fails to restore circulating mucosal-associated invariant T cells. *Eur. J. Immunol.* **2019**, *49*, 1127–1129. [[CrossRef](#)]
28. Wu, X.; Zhang, J.Y.; Huang, A.; Li, Y.Y.; Zhang, S.; Wei, J.; Xia, S.; Wan, Y.; Chen, W.; Yin, Z. Decreased V $\delta$ 2  $\gamma\delta$  T cells associated with liver damage by regulation of Th17 response in patients with chronic hepatitis B. *J. Infect. Dis.* **2013**, *208*, 1294–1304. [[CrossRef](#)]
29. Farcomeni, S.; Moretti, S.; Fimiani, C.; Sulekova, L.F.; Vescio, F.; Sernicola, L.; Maggiorella, M.T.; Remoli, A.L.; Picconi, O.; Mosca, L.; et al. Short- and Long-Term Immunological Responses in Chronic HCV/HIV Co-Infected Compared to HCV Mono-Infected Patients after DAA Therapy. *Pathogens* **2021**, *10*, 1488. [[CrossRef](#)]
30. Amele, S.; Sandri, A.K.; Rodger, A.; Vandekerckhove, L.; Benfield, T.; Milinkovic, A.; Duvivier, C.; Stellbrink, H.; Sambatakou, H.; Chkhartishvili, N.; et al. HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe. *HIV Med.* **2021**, *23*, 684–692. [[CrossRef](#)]